Editor's Note: In this special blog, CEO Betsy J. Lahue sits down with a leading biotech innovation...
Pharmaceutical restructuring is targeting HEOR and Market Access teams despite their critical role in commercial success.
Our report, Value in the Crosshairs, reveals why Value functions are vulnerable and provides a practical framework for demonstrating their commercial impact.
Discover how forward-thinking leaders are transforming Value teams from cost centers to strategic assets.
